Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM(SM) registry

BACKGROUND: Immune related adverse events (irAEs) are associated with immunotherapy for cancer and while results suggest improvement in tumor control and overall survival in those experiencing irAEs, the long-term impact is debated. We evaluated irAE reports related to high dose interleukin-2 therap...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Immunother Cancer
Autores principales: Curti, Brendan, Daniels, Gregory A., McDermott, David F., Clark, Joseph I., Kaufman, Howard L., Logan, Theodore F., Singh, Jatinder, Kaur, Meenu, Luna, Theresa L., Gregory, Nancy, Morse, Michael A., Wong, Michael K. K., Dutcher, Janice P.
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5735508/
https://ncbi.nlm.nih.gov/pubmed/29254506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-017-0307-5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares